Runaway Quarks

When heavy nuclei collide, a quark-gluon plasma is formed. The plasma is subject to strong electric field due to the charge of the colliding nuclei. The electric field can influence the behavior of the quark-gluon plasma. In particular, we might observe an increased number of quarks moving in the direction of that field, as we do in the standard electron-ion plasma. In this paper we show that this phenomenon, called the runaway quarks, does not exist.Comment: 13 pages, uses harvmac.tex, epsf.te

Proposal for FRX-C and multiple-cell Compact Torus experiments

A Compact Torus (CT) is a configuration for plasma confinement that offers possible engineering advantages for fusion power generation such as small size, simple blanket geometry, natural divertor, and spatially separable functions of plasma production and fusion energy generation. Two experiments to study the physics and technology of some particular CT configurations are proposed here as part of the LASL Compact Torus Program Plan. One experiment, FRX-C, is designed to study CT stability and transport properties by scaling the parameters of the existing FRX-B field-reversed theta-pinch experiment to higher temperatures, larger size, and increased plasma lifetime. The second experiment, a modification of the existing Scylla IV-P device, would form a linear array of CTs with the aim of understanding the effect on CT transport of improved plasma confinement on the open field lines outside the separatrix, as well as other multiple-cell effects

The Effect of Coherent Structures on Stochastic Acceleration in MHD Turbulence

We investigate the influence of coherent structures on particle acceleration in the strongly turbulent solar corona. By randomizing the Fourier phases of a pseudo-spectral simulation of isotropic MHD turbulence (Re $\sim 300$), and tracing collisionless test protons in both the exact-MHD and phase-randomized fields, it is found that the phase correlations enhance the acceleration efficiency during the first adiabatic stage of the acceleration process. The underlying physical mechanism is identified as the dynamical MHD alignment of the magnetic field with the electric current, which favours parallel (resistive) electric fields responsible for initial injection. Conversely, the alignment of the magnetic field with the bulk velocity weakens the acceleration by convective electric fields - \bfu \times \bfb at a non-adiabatic stage of the acceleration process. We point out that non-physical parallel electric fields in random-phase turbulence proxies lead to artificial acceleration, and that the dynamical MHD alignment can be taken into account on the level of the joint two-point function of the magnetic and electric fields, and is therefore amenable to Fokker-Planck descriptions of stochastic acceleration.Comment: accepted for publication in Ap

LISSAT Analysis of a Generic Centrifuge Enrichment Plant

The U.S. Department of Energy (DOE) is interested in developing tools and methods for use in designing and evaluating safeguards systems for current and future plants in the nuclear power fuel cycle. The DOE is engaging several DOE National Laboratories in efforts applied to safeguards for chemical conversion plants and gaseous centrifuge enrichment plants. As part of the development, Lawrence Livermore National Laboratory has developed an integrated safeguards system analysis tool (LISSAT). This tool provides modeling and analysis of facility and safeguards operations, generation of diversion paths, and evaluation of safeguards system effectiveness. The constituent elements of diversion scenarios, including material extraction and concealment measures, are structured using directed graphs (digraphs) and fault trees. Statistical analysis evaluates the effectiveness of measurement verification plans and randomly timed inspections. Time domain simulations analyze significant scenarios, especially those involving alternate time ordering of events or issues of timeliness. Such simulations can provide additional information to the fault tree analysis and can help identify the range of normal operations and, by extension, identify additional plant operational signatures of diversions. LISSAT analyses can be used to compare the diversion-detection probabilities for individual safeguards technologies and to inform overall strategy implementations for present and future plants. Additionally, LISSAT can be the basis for a rigorous cost-effectiveness analysis of safeguards and design options. This paper will describe the results of a LISSAT analysis of a generic centrifuge enrichment plant. The paper will describe the diversion scenarios analyzed and the effectiveness of various safeguards systems alternatives

Microwave Spectroscopy

Contains reports on four research projects

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer

This phase 1/2 study evaluated the dose-limiting toxicity and maximum tolerated dose of MLN2704, a humanized monoclonal antibody MLN591 targeting prostate-specific membrane antigen, linked to the maytansinoid DM1 in patients with progressive metastatic castration-resistant prostate cancer

Advances in nuclear instrumentation for safeguards

This paper describes detectors, instrumentation, and analytical methods under development to address the above issues. The authors will describe work underway on room-temperature semiconductors including attempts to model the response of these detectors to improve spectrum analysis procedures and detector design. Computerized tomography is used in many medical and industrial applications; they are developing both gamma-ray and neutron tomography for improved measurements of waste and direct-use materials. Modern electronics and scintillation detectors should permit the development of fast neutron coincidence detectors with dramatically improved signal-to-noise ratios. For active measurements, they are studying several improved neutron sources, including a high-fluence, plasma-based, d-t generator. New analysis tools from information theory may permit one to better combine data from different measurement systems. This paper attempts to briefly describe a range of new sensors, electronics, and data analysis methods under study at Los Alamos and other laboratories to promote discussion of promising technology that they may bring to bear on these important global issues

Solitary skin metastasis from sarcomatoid carcinoma of the bladder: a case report

<p>Abstract</p> <p>Introduction</p> <p>Cutaneous metastases from carcinomas of the bladder are very rare. They are related to advanced stages of the disease and have poor prognosis with low survival rates. The common treatment modality of cutaneous metastases from a primary bladder cancer is wide local excision followed by chemotherapy.</p> <p>Case presentation</p> <p>We report a case of solitary skin metastasis from a rare type of urinary bladder carcinoma in a 68 year-old Caucasian man. Urinary bladder carcinoma metastasizing to the skin is an uncommon finding despite the high incidence of this tumor. Skin metastasis generally presents in the late stages of this disease and indicates a poor outcome.</p> <p>Conclusions</p> <p>Because of the extremely aggressive malignant potential of sarcomatoid carcinomas, the indications for a transurethral resection of the bladder should be carefully assessed and suitable therapeutic strategies should be examined further.</p

Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study

The purpose of the study was to investigate the toxicity and efficacy of the combination of gemcitabine and docetaxel in untreated advanced urothelial carcinoma. Patients with previously untreated, locally advanced/recurrent or metastatic urothelial carcinoma stage-IV disease were eligible. Patients with Performance status: PS ECOG >3 or age >75 years or creatinine clearance <50 ml min−1 were excluded. Study treatment consisted of docetaxel 75 mg m−2 (day 8) and gemcitabine 1000 mg m−2 (days 1+8), every 21 days for a total of six to nine cycles. A total of 31 patients with urothelial bladder cancer, 25 men and six women, aged 42–74 (median 64) years were enrolled. The majority of patients had a good PS (51.6%; PS 0). In all, 15 (48.3%) patients had locally advanced or recurrent disease only and 16 (54.8%) presented with distant metastatic spread, with multiple site involvement in 22.5%. Toxicity was primarily haematologic, and the most frequent grade 3–4 toxicities were anaemia 11 (6.7%) thrombocytopenia eight (4.9%), and neutropenia 45 (27.6%), with 10 (6.1%) episodes of febrile neutropenia. No toxic deaths occurred. A number of patients had some cardiovascular morbidity (38.7%). Nonhaematological toxicities except alopecia (29 patients) were mild. Overall response rate was 51.6%, including four complete responses (12.9%) and 12 partial responses (38.7%), while a further five patients had disease stabilisation (s.d. 16.1%). The median time to progression was 8 months (95% CI 5.1–9.2 months) and the median overall survival was 15 months (95% CI 11.2–18.5 months), with 1-year survival rate of 60%. In conclusion, this schedule of gemcitabine and docetaxel is very active and well tolerated as a first-line treatment for advanced/relapsing or metastatic urothelial carcinoma. Although its relative efficacy and tolerance as compared to classic MVAC should be assessed in a phase III setting, the favourable toxicity profile of this regimen may offer an interesting alternative, particularly in patients with compromised renal function or cardiovascular disease

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Purpose Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we present the outcomes of the CHAARTED (Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) trial with more mature follow-up and focus on tumor volume. Patients and Methods In this phase III study, 790 patients with metastatic hormone-sensitive prostate cancer were equally randomly assigned to receive either ADT in combination with docetaxel 75 mg/mm2 for up to six cycles or ADT alone. The primary end point of the study was overall survival (OS). Additional analyses of the prospectively defined low- and high-volume disease subgroups were performed. High-volume disease was defined as presence of visceral metastases and/or ≥ four bone metastases with at least one outside of the vertebral column and pelvis. Results At a median follow-up of 53.7 months, the median OS was 57.6 months for the chemohormonal therapy arm versus 47.2months for ADT alone (hazard ratio [HR], 0.72; 95% CI, 0.59 to 0.89; P = .0018). For patients with high-volume disease (n = 513), the median OS was 51.2 months with chemohormonal therapy versus 34.4 months with ADT alone (HR, 0.63; 95% CI, 0.50 to 0.79; P \u3c .001). For those with low-volume disease (n = 277), no OS benefit was observed (HR, 1.04; 95% CI, 0.70 to 1.55; P = .86). Conclusion The clinical benefit from chemohormonal therapy in prolonging OS was confirmed for patients with high-volume disease; however, for patients with low-volume disease, no OS benefit was discerned